XML 50 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
Related Parties Transactions (Details Textual) - USD ($)
1 Months Ended 2 Months Ended 3 Months Ended 12 Months Ended
Jan. 26, 2017
Sep. 30, 2015
Dec. 31, 2017
Dec. 31, 2016
Sep. 30, 2017
Sep. 30, 2016
Related Parties Transactions (Textual)            
Amount received from BriVision     $ 4,229,320   $ 4,113,000  
Outstanding loan     950,000   950,000  
Accrued interest     17,460   8,460  
Interest expenses     28,500 74,960 $ 10,170
Aggregate working capital     $ 7,000      
Interest rate percentage     0.00%      
Outstanding advance     $ 7,000   0  
Common stock new issues   $ 51,958     5,850,000 3,250,000
Stock based compensation expenses         138,038 397,960
Additional paid-in capital     13,805,936   13,788,574  
Monthly base rent         5,000  
Rent expenses         $ 52,205 $ 0
Related party transactions, description        

Pursuant to the Investment and Equity Transfer Agreement, Everfront agreed to purchase 2,000,000 common shares of the Company owned by Asiangene at $1.60 per share in a total amount of $3,200,000, of which $160,000 is due before September 15, 2017 and the remaining amount of $3,040,000 is due before December 15, 2017. Asiangene also agreed to loan the proceeds to the Company for working capital purpose. The non-secured loan bears 0% interest rate and is due on demand.

 
Liongene Corporation [Member]            
Related Parties Transactions (Textual)            
Consulting service         $ 70,000  
BioLite [Member]            
Related Parties Transactions (Textual)            
Aggregate working capital     $ 109,220      
Interest rate percentage     0.00%      
Outstanding advance     $ 109,220   0  
Loan agreement [Member]            
Related Parties Transactions (Textual)            
Total commitment $ 950,000          
Loan maturity date Feb. 01, 2018          
Loan agreement, description The loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to pay interest monthly to the lender.          
BioFirst Collaborative Agreement [Member]            
Related Parties Transactions (Textual)            
Outstanding advance     3,000,000   3,000,000  
Due to BioFirst         3,000,000  
Yuangene Corporation [Member]            
Related Parties Transactions (Textual)            
Amount received from BriVision     3,000   3,000  
Aggregate working capital         $ 3,000  
Interest rate percentage         0.00%  
Outstanding advance     3,000   $ 3,000  
Additional paid-in capital         70,000  
Euro-Asia Agreement [Member]            
Related Parties Transactions (Textual)            
Stock based compensation expenses     5,000   55,000  
Kimho Agreement [Member]            
Related Parties Transactions (Textual)            
Stock based compensation expenses     10,000   80,000  
BioLite one [Member]            
Related Parties Transactions (Textual)            
Amount received from BriVision     6,500,000   0  
Asiangene [Member]            
Related Parties Transactions (Textual)            
Amount received from BriVision     160,000   160,000  
Outstanding loan     160,000   160,000  
BioFirst [Member]            
Related Parties Transactions (Textual)            
Amount received from BriVision     3,957,000   3,950,000  
BioLite Inc. [Member]            
Related Parties Transactions (Textual)            
Amount received from BriVision     109,220    
Eugene Jiang [Member]            
Related Parties Transactions (Textual)            
Amount received from BriVision     100      
Aggregate working capital     $ 100      
Interest rate percentage     0.00%      
Outstanding advance     $ 100   0  
Co-Dev Agreement [Member]            
Related Parties Transactions (Textual)            
Amount received from BriVision     450,000      
Common stock new issues     $ 2,550,000   $ 3,000,000